Anebulo Pharmaceuticals, Inc.
ANEB OTC
SEC CIK 1815974
Follow Anebulo Pharmaceuticals
Weekly email: filings, results, news
Net income
−$2M
+18.8% vs same quarter last year
EPS, diluted
−$0.05
+44.4% vs same quarter last year
Operating cash flow
−$1.3M
+6.6% vs same quarter last year
Operating income
−$2.6M
−1.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$8.5M |
| FY24 | −$8.2M |
| FY23 | −$11.7M |
| FY22 | −$6.8M |
| FY21 | −$30.3M |
| FY20 | - |
News
No stories filed under Anebulo Pharmaceuticals yet - coverage appears here as the news feed clusters it.